Survodutide (10MG)
Survodutide is a dual-agonist peptide targeting both GLP-1 and glucagon receptors for enhanced metabolic effects. The glucagon component increases energy expenditure and fat oxidation while GLP-1 controls appetite and glucose regulation. This dual mechanism offers potentially superior weight loss and metabolic benefits compared to GLP-1-only compounds. Key Benefits: – Dual Mechanism – Activates both GLP-1 and glucagon pathways – Enhanced Fat Burning – Glucagon increases energy expenditure and lipolysis – Appetite Control – GLP-1 action reduces hunger and food intake – Glucose Regulation – Improves insulin sensitivity and blood sugar control – Liver Health – Researched for reducing liver fat (MASH/NAFLD) – Body Composition – Targets fat loss while supporting metabolic health Researched for weight management, metabolic health, and fatty liver disease.
Survodutide is a dual-agonist peptide targeting both GLP-1 and glucagon receptors for enhanced metabolic effects. The glucagon component increases energy expenditure and fat oxidation while GLP-1 controls appetite and glucose regulation. This dual mechanism offers potentially superior weight loss and metabolic benefits compared to GLP-1-only compounds. Key Benefits: – Dual Mechanism – Activates both GLP-1 and glucagon pathways – Enhanced Fat Burning – Glucagon increases energy expenditure and lipolysis – Appetite Control – GLP-1 action reduces hunger and food intake – Glucose Regulation – Improves insulin sensitivity and blood sugar control – Liver Health – Researched for reducing liver fat (MASH/NAFLD) – Body Composition – Targets fat loss while supporting metabolic health Researched for weight management, metabolic health, and fatty liver disease.
| Attributes | Value |
|---|---|
| Packs |
10 pack, 5 pack, Single |
Frequently bought together
-
Adamax 940 (10mg)
$41.00 -
AOD (5mg)
$45.00 -
ARA-290 (18mg)
$45.00 -
BPC-157 10mg
$56.00 -
Cagrilintide (10MG)
$75.00 -
CJC no Dac (10mg)
$52.00 -
DSIP (5MG)
$30.00 -
Fox04-DRI (10mg)
$80.00








